Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Priority-Setting Includes Fewer Meetings With NDA Sponsors

This article was originally published in The Pink Sheet Daily

Executive Summary

Office of New Drugs Director Jenkins tells DIA that agency is making “strategic decisions” about how many sponsor meetings it can schedule.

You may also be interested in...



United Therapeutics’ Inhaled Treprostinil May Get Second Quarter 2009 Action Date

NDA for the new formulation of Remodulin for pulmonary arterial hypertension was filed June 27.

United Therapeutics’ Inhaled Treprostinil May Get Second Quarter 2009 Action Date

NDA for the new formulation of Remodulin for pulmonary arterial hypertension was filed June 27.

FDA Puts “Safety First” For Post-Market Issues

Agency’s two-pronged approach to drug safety includes bolstering internal processes and equipping physicians with better tools for safe prescribing habits.

Topics

UsernamePublicRestriction

Register

PS067986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel